1. Jacobsen W, Unger M, Niemann C, Baloum M, Hirai S, Benet LZ, Christians U. Automated, Fast and Sensitive Quantification of Drugs in Human Plasma by LC/LC-MS: Simultaneous Quantification of Six Protease Inhibitors and Three Non-Nucleoside Transcriptase Inhibitors. Ther Drug Monit 2004; 26: 546-562.

2. Christians U, Gottschalk S, Miljus J, Hainz C, Benet LZ, Leibfritz D, Serkova N. Alterations in Glucose Metabolism by Cyclosporine in Rat Brain Slices Link to Oxidative stress: interactions with mTOR inhibitors. Br J Pharmacol 2004; 143: 388-396.

3. Lam TT, Hausen B, Hook L, Lau M, Higgins J, Christians U, Jacobsen W, BaluomM, Duthaler R, Katopodis A, Chavez G, Cozzi E, Harrison R, Schuurman HJ, Borie D, Morris RE. The effect of soluble complement receptor type 1 on acute humoral xenografts rejection in hDAF-transgenic pig-to-primate life-supporting kidney xenografts. Xenotransplantation 2005; 12: 20-29.

4. Wijkstrom M, Kirchhof N, Graham M, Ingulli E, Colvin RB, Christians U, Hering BJ, Schuurman HJ. Cyclosporine toxicity in immunosuppressed streptozotocin-diabetic nonhuman primates. Toxicology. 2005; 207: 117-127.

5. Tissot van Patot MC, Leadbetter G, Keyes LE, Bendrick-Peart J, Beckey VE, Christians U, Hackett P. Greater free plasma VEGF and lower soluble VEGF receptor-1 in acute mountain sickness. J Appl Physiol. 2005; 98:1626- 1629.

6. Zhou H, Zhang Y, Biggs DL, Manning MC, Randolph TW, Christians U, Hybertson BM, Ng KY. Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages. J Control Release 2005; 107: 288-299.

7. Frassetto L, Baluom M, Jacobsen W, Christians U, Roland ME, Stock PG, Carlson L, Benet LZ. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation 2005; 80:13-17.

8. Filler G, Womiloju T, Feber J, Lepage N, Christians U. Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure. Am J Transplant 2005; 5: 2005-2010.

9. Trotter JF, Osborne JC, Heller M, Christians U. Effect of hepatitis C infection on tacrolimus doses and blood levels in liver transplantation recipients. Aliment Pharmacol Ther 2005; 22: 37-44.

10. Christians U, Reisdorph N, Klawitter J, Schmitz V. Biomarkers of immuno-suppressive drug toxicity. Curr Opin Organ Transplant 2005; 10(4): 284-294.

11. Christians U, Schmitz V, Haschke M. Functional interactions between p-glycoprotein and CYP3A in drug metabolism. Exp Opin Drug Metab Toxicol 2005; 4: 641-654

12. Serkova NJ, Christians U. Biomarkers for toxicodynamic monitoring of immunosuppressants: NMR-based quantitative metabonomics on the blood. Ther Drug Monit 2005; 27:733-737

13. Zhang YL, Bendrick-Peart J, Strom T, Haschke M, Christians U. Development and validation of a high-throughput assay for quantification of the proliferation inhibitor ABT-578 using LC/LC-MS/MS in blood and tissue samples. Ther Drug Monit 2005; 27: 770-778.

14. Hering BJ, Wijkstrom M, Graham ML, Hårdstedt M, Aasheim T, Tun J, Ansite JD, Nakano M, Cheng J, Moran K, Christians U, Finnegan C, Mills CD, Sutherland DE, Bansal-Pakala P, Murtaugh MP, Kirchhof N, Schuurman H-J. Prolonged diabetes after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed non-primates without ani-Gal antibody manipulation. Nat. Med. 2006; 12(3): 301-303.

15. Christians U, Strom T, Zhang YL, Steudel W, Schmitz V, Trump S, Haschke M. Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics. Ther Drug Monit 2006; 28:39-44.

16. Patot MC, Hill AE, Dingmann C, Gaul L, Fralick K, Christians U, Honigman B, Salman MD. Risk of impaired coagulation in warfarin patients ascending to altitude (>2400 m). High Alt Med Biol. 2006; 7:39-46.

17. Filler G, Lathia A, Leblanc C, Christians U. Unexpectedly high exposure to enteric-coated mycophenolate sodium upon once-daily dosing. Pediatr Nephrol. 2006 21:1206-1208.

18. Filler G, Rocha de Barros V, Jagger JE, Christians U. Cyclosporine twice or three times daily dosing in pediatric transplant patients. It is not the same! Pediatr Transplantation 2006; 10: 953-956

19. Filler G, Gow R, Nadarajah R, Jacob P, Johnson G, Zhang YL, Christians U. Pharmacokinetics of pyridostigmine in a child with postural tachycardia syndrome. Pediatrics 2006;118:1563-1568.

20. Schmitz V, Klawitter J, Bendrick-Peart J, Beckey V, Laudi S, Neumann U, Schoening W, Christians U, Puhl G. Graft flushing with histidine-tryptophane-ketoglutarate (HTK) followed by extended cold preservation in University of Wisconsin (UW) solution in a rat kidney transplantation model- An improved preservation protocol? Eur J Surg Res 2006; 38:388-398.

21. Ng KY, Zhou H, Zhang YL, Hybertson B, Randolph T, Christians U. Quantification of isoniazid and acetylisoniazid in rat plasma and alveolar macrophages by liquid chromatography-tandem mass spectrometry with on-line extraction. J Chromatogr B 2007; 847: 188-198.

22. Schmelzer E, Acikgoez A, Fruhauf NR, Crome O, Klempnauer J, Christians U, Bader A. Biotransformation of cyclosporin in primary rat, porcine and human liver cell co-cultures. Xenobiotica 2006; 36(8):693-708.

23. Nagata H, Nishitai R, Shirota C, Zhang JL, Koch CA, Cai J, Awwad M, Schuurmann HJ, Christians U, Abe M, Baranowski-Kortylewicz J, Platt JL, Fox IJ. Prolonged survival of porcine hepatocytes in cynomolgus monkeys. Gastroenterology 2007; 132: 321-329.

24. Laudi S, Weimann J, Haschke M, Trump S, Schmitz V, Christians U, Kaisers U, Steudel W. Worsening of long-term myocardial function after successful pharmacological pretreatment with cyclosporine. J Physiol Pharmacol 2007; 58: 19-32.


25. Perry TW, Christians U, Trotter JF, Bendrick-Peart JR. Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant patients. Clin Transplantation 2007; 21: 413-416.

26. Klawitter J, Schmitz V, Klawitter J, Leibfritz D, Christians U. Development and validation of a rapid assay for the quantification of 11 nucleotides in tissue samples using 2-dimensional liquid chromatography-electrospray ionization mass spectrometry. Anal Biochem 2007; 365: 230-239.

27. Haschke M, Zhang YL, Kahle C, Klawitter J, Korecka M, Shaw LM, Christians U. Quantification of 15-F2t-isoprostane in human urine and plasma using high-performance liquid chromatography – atmospheric pressure chemical ionization-tandem mass spectrometry. Clin Chem 2007; 53:489-497.

28. Laudi S, Trump S, Schmitz V, West J, McMurtry IF, Mutlak H, Christians U, Weimann J, Kaisers U, Steudel W. Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin. Am J Physiol Lung Cell Mol Physiol. 2007; 293: L630-638.

29. Strom T, Haschke M, Boyd J, Roberts M, Arabshahi L, Marbach P, Christians U. Cross reactivity of the major everolimus metabolites with the Innofluor Certican immunoassay for therapeutic drug monitoring of everolimus. Ther Drug Monit 2007 29:743-749.

30. Strom T, Haschke M, Bendrick-Peart J, Boyd J, Roberts M, Arabshahi L, Marbach P, Christians U. Everolimus metabolite patterns in the blood of kidney transplant patients. Ther Drug Monit 2007; 29: 592-599

31. Laudi S, Steudel W, Jonscher K, Schöning W, Schniedewind B, Kaisers U, Christians U, Trump S. Comparison of lung proteome profiles in two rodent models of pulmonary artery hypertension. Proteomics 2007; 7: 2469-2478.

32. Klawitter J, Rivard CJ, Brown LM, Capasso JM, Almeida NE, Maunsbach AB, Pihakaski-Maunsbach K, Berl T, Leibfritz D, Christians U, Chan L. A metabonomic and proteomic analysis of changes in IMCD3 cells chronically adapted to hypertonicity. Nephron Physiol. 2008; 109: 1-10.

33. Christians U, Klawitter J, Bendrick-Peart J, Schöning W, Schmitz V. Toxicodynamic therapeutic drug monitoring of immunosuppressants: promises, reality and challenges. Ther Drug Monit 2008; 30: 151-158

34. Filler G, Bendrick-Peart J, Christians U. Pharmacokinetics of mycophenolic mofetil and sirolimus in children. Ther Drug Monit 2008; 30: 138-142.

35. Clavijo C, Bendrick-Peart J, Zhang YL, Johnson G, Gasparic A, Christians U. An automated, highly sensitive LC-MS/MS assay for the quantification of the opiate antagonist naltrexone and its major metabolite 6beta-naltrexol in dog and human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 874: 33-41.

36. Kupfer R, Swanson L, Chow S, Staub RE, Zhang YL, Cohen I, Christians U. Oxidative in vitro metabolism of liquiritigenin, a bioactive compound isolated from the Chinese herbal selective estrogen beta-receptor agonist MF101. Drug Metab Dispos. 2008; 11:2261-2269.

37. Ostojic M, Sagic D, Jung R, Zhang YL, Nedeljkovic M, Mangovski L, Stojkovic S, Debeljacki D, Colic M, Beleslin B, Milosavljevic B, Orlic D, Topic D, Karanovic N, Paunovic D, Christians U; NOBORI PK Investigators. The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study. Catheter Cardiovasc Interv. 2008; 72: 901-908.

38. Filler G, Bendrick-Peart J, Strom T, Zhang YL, Johnson G, Christians U. Characterization of sirolimus metabolites in pediatric solid organ transplant recipients. Pediatr Transplant. 2009, 13; 44-53

39. Klawitter J, Bendrick-Peart J, Rudolph B, Beckey V, Klawitter J, Haschke M, Rivard C, Chan L, Leibfritz D, Christians U, Schmitz V. Urine metabolites reflect time-dependent effects of cyclosporine and sirolimus on rat kidney function. Chem Res Toxicol. 2009; 22: 118-128.

40. Elkiweri IA, Zhang YL, Christians U, Ng KY, Tissot van Patot MC, Henthorn TK. Competitive substrates for p-glycoprotein and organic anion protein transporters differentially reduce blood organ transport of fentanyl and loperamide: pharmacokinetics and pharmacodynamics in Sprague-Dawley rats. Anesth Analg. 2009;108: 149-159.

41. Schmitz V, Klawitter J, Bendrick-Peart J, Puhl G, Haschke M, Klawitter J, Consoer J, Rivard CJ, Chan L, Tran ZV, Leibfritz D, Christians U. Metabolic profiles in urine reflect nephrotoxicity of sirolimus and cyclosporine following rat kidney transplantation. Nephron 2009; 111: e80-91.

42. Klawitter J, Anderson N, Klawitter J, Christians U, Leibfritz D, Eckhardt SG, Serkova NJ. Time-dependent effects of imatinib in human leukemia cells: A kinetic NMR-profiling study. Brit J Cancer 2009; 100: 923-931.

43. Klawitter J, Kominsky DJ, Brown JL, Klawitter J, Christians U, Leibfritz D, Melo JV, Eckhardt SG, Serkova NJ. Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. Br J Pharmacol. 2009;158:588-600.

44. Klawitter J, Zhang YL, Klawitter J, Anderson N, Serkova NJ, Christians U. Development and validation of an assay for the quantification of imatinib using LC/LC-MS/MS in human whole blood and cell culture. Biomed Chromatogr. 2009; 23: 1251-1258.

45. Tissot van Patot MC, Serkova NJ, Haschke M, Kominsky DJ, Roach RC, Christians U, Henthorn TK, Honigman B. Enhanced leukocyte HIF-1alpha and HIF-1 DNA binding in humans after rapid ascent to 4300m. Free Radic Biol Med. 2009; 46:1551-1557.

46. Marusyk A, Casa´s-Selves M, Henry CJ, Zaberezhnyy V, Klawitter J, Christians U, DeGregori J. Irradiation alters selection for oncogenic mutations in hematopoietic progenitors. J. Cancer Res. 2009; 69:7262- 7269.

47. Clavijo C, Storm T , Moll V , Betts R, Zhang YL, Christians U, Bendrick-Peart J. Development and validation of a semi-automated assay for the highly sensitive quantification of Biolimus A9 in human whole blood using high performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009; 877: 3506-3514.

48. Prior JE, Shokati T, Christians U, Gill RT. Identification and characterization of a bacterial cytochrome P450 for the metabolism of diclofenac. Appl Microbiol Biotechnol 2010; 85:625-33

49. Thethi TK, Rao A, Kawji H, Mallik T, Yau CL, Christians U, Fonseca V. Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion. J Diabetes Complications 2010; 24: 73-78.

50. Christians U, Klawitter J, Clavijo C. Bioequivalence testing of immunosuppressants: concepts and misconceptions. Kidney Int 2010; 77 (suppl 115): S1-S7.

51. Klawitter J, Klawitter J, Kushner E, Jonscher KR, Bendrick-Peart J, Leibfritz D, Christians U, Schmitz V. Association of immunosuppressant-induced protein changes in the rat kidney with changes in urine metabolite patterns: A proteo-metabonomic study. J Proteome Res 2010; 9: 865-75

52. Steudel W, Dingmann C, Zhang YL, Bendrick-Peart J, Clavijo C, Shulze J, Betts R, Christians, U. A randomized, double-blind, placebo-controlled, single intravenous dose escalation study to evaluate the safety, tolerability and pharmacokinetics of the novel coronary smooth muscle cell proliferation inhibitor Biolimus A9 in healthy individuals. J Clin Pharmacol 2011; 51: 29-39.

53. Klawitter J, Gottschalk S, Hainz C, Leibfritz D, Christians U, Serkova NJ. Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism. Chem Res Toxicol 2010; 23: 608-619.

54. Klawitter J, Haschke M, Kahle C, Dingmann C, Klawitter J, Leibfritz D, Christians U. Toxicodynamic effects of ciclosporin are reflected by metabolite profiles in the urine of healthy individuals after a single dose. Br J Clin Pharmacol 2010; 70: 241-251.

55. Klawitter J, Shokati T, Moll V, Christians U, Klawitter J. Effects of lovastatin on breast cancer cells: a proteo-metabonomic study. Breast Cancer Res 2010; 12(2):R16.

56. Tada N, Virmani R, Grant G, Bartlett L, Black A, Clavijo C, Christians U, Betts R, Savage D, Su S, Shulze J, Kar S. Polymer-free biolimus A9 coated stent demonstrates more sustained intimal inhibition, improved healing and reduced inflammation in comparison to a polymer-coated sirolimus eluting Cypher stent in a porcine model. Circulation Cardiovasc Interv 2010; 3:174-183.

57. Fæste CK, Christians U, Egaas E, Jonscher KR. Characterization of potential allergens in fenugreek (Trigonella foenum-graecum) using patient sera and MS-based proteomic analysis. J Proteomics 2010; 73:1321-1333.

58. Stevens KE, Cornejo B, Adams CE, Zheng L, Yonchek J, Hoffman KL, Christians U, Kem WR. Continuous administration of a selective alpha7 nicotinic partial agonist, DMXBA, improves sensory inhibition without causing tachyphylaxis or receptor upregulation in DBA/2 mice. Brain Res. 2010; 1352:140-146.

59. Angst MS, Phillips NG, Drover DR, Tingle M, Galinkin JL, Christians U, Swan GE, Lazzeroni LC, Clark JD. Opioid pharmacogenomics using a twin study paradigm: methods and procedures for determining familial aggregation and heritability. Twin Res Hum Genet. 2010; 13: 412-425.

60. Ostojic MC, Perisic Z, Sagic D, Jung R, Zhang YL, Bendrick-Peart J, Betts R, Christians U. The pharmacokinetics of Biolimus A9 after elution from the BioMatrix II stent in patients with coronary artery disease: The Stealth PK study. Eur J Clin Pharmacol 2011; 67: 389-398.

61. Klawitter J, Haschke M, Shokati T, Klawitter J, Christians U. Quantification of 15-F2t-isoprostane in human plasma and urine: ELISA and LC-MS/MS results cannot be compared. Rapid Commun Mass Spectrom 2011; 25: 463-468.

62. Christians U, Klawitter J, Klawitter J, Brunner N, Schmitz V. Biomarkers of immunosuppressant organ toxicity after transplantation- status, concepts and misconceptions. Expert Opin Drug Metabol Toxicol 2011; 7:175-200

63. Christians U, Klawitter J, Hornberger A, Klawitter J. How unbiased is non-targeted metabolomics and is targeted pathway screening the solution? Curr Pharm Biotechnol 2011; 12:1053-1066

64. Fæste CF, Rønning TF, Christians U, Granum PE. Liquid chromatography and mass spectrometry in food allergen detection. J Food Protect 2011; 74:316-45.

65. Gottschalk S, Cummins CL, Leibfritz D, Christians U, Benet LZ, Serkova NJ. Age and sex differences in the effects of the immunosuppressants cyclosporine, sirolimus and everolimus on rat brain metabolism.
Neurotoxicol 2011; 32:50-57

66. Cohen MN, Christians U, Henthorn TK, Tran ZV, Moll V, Zuk J, Galinkin JL. Pharmacokinetics of single-dose intravenous ketorolac in infants aged 2-11 months. Anesth Analgesia 2011; 112: 655-660.

67. Thethi T, Rajapurkar M, Walker P, McDuffie R, Goff D, Probstfield J, Yau C, Shah S, Christians U, Buse J, Fonseca V. Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria — a sub-study of the ACCORD trial. Clin Chem 2011; 57: 341-344.

68. Klawitter J, Klawitter J, Gurshtein J, Corby K, Fong S, Tagliaferri M, Quattrochi M, Cohen I, Shtivelman E, Christians U. Bezielle (BZL101)-induced oxidative stress damage followed by redistribution of metabolic fluxes in breast cancer cells: a combined proteomic and metabolomic study. Int J Cancer 2011; 129: 2945-2957.

69. Banerjee S, Gianino SM, Gao F, Christians U, Gutmann DH. Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically-engineered mouse model of Nf1-deficient astrocytes. Mol Cancer Ther. 2011 10:279-291

70. Clavijo CF, Hoffman KL, Thomas JJ, Carvalho B, Chu LF, Drover DR, Hammer GB, Christians U, Galinkin JL. A sensitive assay for the quantification of morphine and its active metabolites in human plasma and dried blood spots using high performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2011; 400: 715-728.

71. Strom T, Klawitter J, Klawitter J, Hoffman K, Schiebel H-M, Christians U. Structural identification of SAR-943 metabolites generated by human liver microsomes in vitro using mass spectrometry in combination with analysis of fragmentation patterns. J Mass Spectrom 2011; 46: 615-624.

72. Cooper JE, Christians U, Wiseman AC. Everolimus in kidney transplantation. Transplant Res Risk Management 2011; 3: 1-16.

73. Clavijo CF, Thomas JJ, Cromie M, Schniedewind B, Hoffman KL, Christians U, Galinkin JL. A low blood volume LC-MS/MS assay for the quantification of fentanyl and its major metabolites norfentanyl and despropionyl fentanyl in children. J Sep Sci. 2011, 34 : 3568-3577.

74. Klepacki J, Klawitter J, Bendrick-Peart J, Schniedewind B, Heischmann S, Shokati T, Christians U, Klawitter J. A high-throughput U-HPLC-MS/MS assay for the quantification of mycophenolic acid and its major metabolites mycophenolic acid glucuronide and mycophenolic acid acyl-glucuronide in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2012; 883-884: 113-119.

75. Aquilante CL, Kiser JJ, Anderson PL, Christians U, Kosmiski LA, Daily EB, Hoffman KL, Hopley CW, Predhomme JA, Schniedewind B, Sidhom MS. Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin. J Clin Pharmacol 2012, 52: 1725-1738.

76. Christians U, Klepacki J, Shokati T, Klawitter J, Klawitter J. Mass spectrometry-based multiplexing for the analysis of biomarkers in drug development and clinical diagnostics- how much is too much? Microchem J 2012; 105: 32-38.

77. Pacheco-López G, Doenlen R, Krügel U, Arnold M, Wirth T, Riether C, Engler A, Niemi MB, Christians U, Engler H, Schedlowski M. Neurobehavioural activation during peripheral immunosuppression. Int J Neuropsychopharmacol. 2013; 16: 137-149.

78. Leitman DC, Christians U. MF101 : a multi-component botanical selective estrogen receptor beta modulator for the treatment of menopausal vasomotor symptoms. Expert Opin Investig Drugs. 2012 ; 21 :1031-1042

79. Klawitter J, Klawitter J, Schmitz V, Brunner N, Crunk A, Corby K, Bendrick-Peart J, Leibfritz D, Edelstein CL, Thurman JM, Christians U Low-salt diet and cyclosporine nephrotoxicity: changes in kidney cell metabolism. J Proteome Res 2012; 11: 5135-5144

80. Clavijo CF, Rzasa Lynn R, Christians U, Galinkin J. Intranasal Fentanyl for breakthrough pain control. Clinical Medicine Insights: Therapeutics 2012: 4; 241–250

81. Macy ME, Duncan T, Whitlock J, Hunger SP, Boklan J, Narendaren A, Herzog C, Arceci RJ, Bagatell R, Trippett T, Christians U, Rolla K, Ivy PS, Gore L. A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors. Pediatr Blood Cancer 2013; 60: 230-236

82. Bohra R, Schöning W, Klawitter J, Brunner N, Schmitz V, Shokati T, Lawrence R, Abelaez MF, Schneidewind B, Christians U, Klawitter J. Everolimus and sirolimus in combination with cyclosporine have different effects on renal metabolism in the rat. PLoS One 2012 ; 7:e48063

83. Bohra R, Klepacki J, Klawitter J, Klawitter J, Thurman J, Christians U. Proteomics and metabolomics in renal transplantation- Quo vadis? Transplant Int 2013; 26: 225-241

84. Klawitter J, Klawitter J, Agardi E, Corby K, Leibfritz D, Lowe BD, Christians U, Seres T. Association of DJ-1/PTEN/AKT and ASK1/p38 mediated cell signaling with ischemic cardiomyopathy. Cardiovasc Res 2013; 97: 66-76.

85. Niederlechner S, Baird C, Klawitter J, Christians U, Wischmeyer P. Fibronectin-integrin signaling is required for L-glutamine’s protection against gut injury. PLoS One 2012 ; 7: e48063

86. Chitnis SD, Ogasawara K, Schniedewind B, Gohh RY, Christians U, Akhlaghi F. Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism. Xenobiotica. 2013; 43: 641-649.

87. Rhazzaghi H, Tempczyk-Russell A,Santorico SA, Shokati T, Christians U, Churchill MEA. Genetic and structure-function studies of missense mutations in human endothelial lipase. PLoS One 2013, 8: e55716

88. Taylor RR, Hoffman KL, Schniedewind B, Clavijo C, Galinkin JL, Christians U. Comparison of the quantification of acetaminophen in plasma, cerebrospinal fluid and dried blood spots using high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2013; 83:1-9.

89. Klepacki J, Brunner N, Schmitz V, Klawitter J, Christians U, Klawitter J. Development and validation of an LC-MS/MS assay for the quantification of the trans-methylation pathway intermediates S-adenosylmethionine and S-adenosylhomocysteine in human plasma. Clin Chim Acta 2013; 421: 91-97

90. Fernandez-Bustamante A, Klawitter J, Wilson P, Elkins ND, Agazio A, Shibata T, Uchida K, Christians U, Repine JE. Early increase in alveolar macrophage prostaglandin 15d-PGJ2 precedes neutrophil recruitment into lungs of cytokine-insufflated rats. Inflammation 2013; 36: 1030-40.

91. Emoto C, Fukuda T, Cox S, Christians U, Vinks AA. Development of a physiologically-based pharmacokinetic model for sirolimus: Predicting bioavailability based on intestinal CYP3A content. CPT Pharmacometrics Syst Pharmacol. 2013; 2: e59.

92. Klawitter J, Zafar I, Klawitter J, Pennington AT, Klepacki J, Gitomer BY, Schrier RW, Christians U, Edelstein CL. Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease. BMC Nephrol. 2013; 14: 165.

93. Lemos PA, Farooq V, Takimura CK, Gutierrez PS, Virmani R, Kolodgie F, Christians U, Kharlamov A, Doshi M, Sojitra P, van Beusekom HM, Serruys PW. Emerging technologies: polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. EuroIntervention. 2013; 9: 148-156.

94. Ogasawara K, Chitnis SD, Gohh RY, Christians U, Akhlaghi F. Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients. Clin Pharmacokinet. 2013; 52: 751-762.

95. Frassetto L, Floren L, Barin B, Browne M, Wolfe A, Roland M, Stock P, Carlson L, Christians U. Changes in clearance, volume and bioavailability of immunuosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients. Biopharm Drug Dispos. 2013 ; 34: 442-451.

96. Pian P, Labovitz E, Hoffman K, Clavijo CF, Rzasa Lynn R, Galinkin JL, Vinks AA, Malik P, Christians U. Quantification of the 5-lipoxygenase inhibitor zileuton in human plasma using high performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2013; 937: 79-83.

97. Klawitter J, Klawitter J, McFann K, Pennington AT, Abebe KZ, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Gitomer B, Christians U, Schrier RW. Bioactive lipid mediators in polycystic kidney disease. J Lipid Res. 2013 ; 55: 1139-1149.

98. Tak E, Ridyard D, Kim JH, Zimmerman M, Werner T, Wang XX, Shabeka U, Seo SW, Christians U, Klawitter J, Moldovan R, Garcia G, Levi M, Haase V, Ravid K, Eltzschig HK, Grenz A. CD73-Dependent generation of adenosine and endothelial adora2b signaling attenuate diabetic nephropathy. J Am Soc Nephrol. 2013 Nov 21. [Epub ahead of print] PubMed PMID: 24262796.

99. Renner B, Klawitter J, Goldberg R, McCullough JW, Ferreira VP, Cooper JE, Christians U, Thurman JM. Cyclosporine induces endothelial cell release of complement-activating microparticles. J Am Soc Nephrol. 2013 Nov;24(11):1849-1862.

100. Klawitter J, Klawitter J, Schmitz V, Shokati T, Epshtein E, Thurman JM, Christians U. Mycophenolate mofetil enhances the negative effects of sirolimus and tacrolimus on rat kidney cell metabolism. PLoS One. 2014; 9: e86202.

101. Fernandez-Bustamante A, Klawitter J, Repine JE, Agazio A, Janocha AJ, Shah C, Moss M, Douglas IS, Tran ZV, Erzurum SC, Christians U, Seres T. Early effect of tidal volume on lung injury biomarkers in surgical patients with healthy lungs. Anesthesiology. 2014 May 7. [Epub ahead of print] PubMed PMID: 24809976.

102. Gardner LA, Klawitter J, Gregory MA, Zaberezhnyy V, Baturin D, Pollyea DA, Takebe N, Christians U, Gore L, DeGregori J, Porter CC. Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia. Am J Hematol. 2014 May 31. [Epub ahead of print] PubMed PMID: 24891015.

103. Shihab F, Christians U, Smith L, Wellen JR, Kaplan B. Focus on mTOR inhibitors and tacrolimus in renal transplantation: Pharmacokinetics, exposure-response relationships, and clinical outcomes. Transpl Immunol. 2014; 31: 22-32.

104. Kruse Fæste C, Jonscher KR, Dooper MMWB, Egge-Jacobsen W, Moen A, Daschner A, Egaas E, Christians U. Characterisation of potential novel allergens in thefish parasite Anisakis simplex. EuPA Open Proteomics 2014 ; 4: 140-155.

Comments are closed.